Compare ORN & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORN | IVVD |
|---|---|---|
| Founded | 1994 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 411.7M | 437.1M |
| IPO Year | 2007 | 2021 |
| Metric | ORN | IVVD |
|---|---|---|
| Price | $11.57 | $1.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $16.25 | $8.75 |
| AVG Volume (30 Days) | 258.2K | ★ 3.4M |
| Earning Date | 04-28-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 220.00 | 79.02 |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $852,260,000.00 | $53,426,000.00 |
| Revenue This Year | $8.50 | $61.57 |
| Revenue Next Year | $7.83 | $41.42 |
| P/E Ratio | $195.33 | ★ N/A |
| Revenue Growth | 7.01 | ★ 110.47 |
| 52 Week Low | $5.68 | $0.49 |
| 52 Week High | $15.00 | $3.07 |
| Indicator | ORN | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 50.83 | 55.73 |
| Support Level | $9.85 | $1.41 |
| Resistance Level | $11.85 | $1.77 |
| Average True Range (ATR) | 0.46 | 0.15 |
| MACD | 0.13 | 0.05 |
| Stochastic Oscillator | 63.64 | 83.33 |
Orion Group Holdings Inc is a specialty construction company serving the infrastructure, industrial, and building sectors, providing services both on and off the water in the continental United States, Alaska, Canada, and the Caribbean Basin through its marine segment and its concrete segment. Its marine segment provides construction and dredging services relating to marine transportation facility construction, marine pipeline construction, marine environmental structures, dredging of waterways, channels and ports, environmental dredging, design, and specialty services. The concrete segment generates maximum revenue and provides construction services for commercial, industrial, multi-family residential, and public projects, including the data center market.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.